Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?

Surgery

Volumn 145, Issue 1, 2009, Pages 69-75

  Maire, Frédérique ^a   Hammel, Pascal ^a   Kianmanesh, Reza ^a   Hentic, Olivia ^a   Couvelard, Anne ^a   Rebours, Vinciane ^a   Zappa, Magaly ^a   Raymond, Eric ^a   Sauvanet, Alain ^a   Louvet, Christophe ^b   Lévy, Philippe ^a   Belghiti, Jacques ^a   Ruszniewski, Philippe ^a  

^a BEAUJON HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; FLUOROURACIL; STREPTOZOCIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL OBSERVATION; CONTROLLED STUDY; DIGESTIVE SYSTEM TUMOR; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; ENDOCRINE TUMOR; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS TUMOR; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; ENDOCRINE GLAND NEOPLASMS; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STREPTOZOCIN; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57149095627     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.08.007     Document Type: Article

References (34)

1. Madeira I., Terris B., Voss M., Denys A., Sauvanet A., Flejou J.F., et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43 (1998) 422-427
2. Jaeck D., Oussoultzoglou E., Rosso E., Greget M., Weber J.C., and Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 240 (2004) 1037-1049
3. Norton J.A., Fraker D.L., Alexander H.R., Gibril F., Liewehr D.J., Venzon D.J., et al. Surgery increases survival in patients with gastrinoma. Ann Surg 244 (2006) 410-419
4. Fendrich V., Langer P., Celik I., Bartsch D.K., Zielke A., Ramaswamy A., et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 244 (2006) 845-853
5. Schurr P.G., Strate T., Rese K., Kaifi J.T., Reichelt U., Petri S., et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 245 (2007) 273-281
6. Sarmiento J.M., Heywood G., Rubin J., Ilstrup D.M., Nagorney D.M., and Que F.G. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197 (2003) 29-37
7. Norton J.A., Warren R.S., Kelly M.G., Zuraek M.B., and Jensen R.T. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134 (2003) 1057-1063
8. Elias D., Lasser P., Ducreux M., Duvillard P., Ouellet J.F., Dromain C., et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 133 (2003) 375-382
9. Kianmanesh R., Sauvanet A., Hentic O., Couvelard A., Lévy P., Vilgrain V., et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 247 (2008) 659-665
10. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
11. Nordlinger B., Sorbye H., Glimelius B., Poston G.J., Schlag P.M., Rougier P., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008) 1007-1016
12. Weber H.C., Venzon D.J., Lin J.T., Orbuch M., Strader D.B., and Gibril F. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108 (1995) 1637-1649
13. Moertel C.G., Kvols L.K., O'Connell M.J., O'Connell M.J., and Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 (1991) 227-232
14. Moertel C.G., Johnson C.M., McKusick M.A., Martin Jr. J.K., Nagorney D.M., Kvols L.K., et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120 (1994) 302-309
15. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., and Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519-523
16. Eriksson B., Skogseid B., Lundqvist G., Wide L., Wilander E., and Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65 (1990) 1883-1890
17. Bukowski R.M., Tangen C., Lee R., Macdonald J.S., Einstein Jr. A.B., Peterson R., et al. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. J Clin Oncol 10 (1992) 1914-1918
18. Cheng P.N., and Saltz L.B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 (1999) 944-948
19. Engstrom P.F., Lavin P.T., Moertel C.G., Folsch E., and Douglass H.O. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2 (1984) 1255-1259
20. Solcia E., and Klöppel G. Sobin LH in collaboration with 9 pathologists from 4 countries. Histological typing of endocrine tumours. World Health Organization: International Histological Classification of Tumours. 2nd ed. (2000), Springer
21. Kloppel G., Perren A., and Heitz P.U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014 (2004) 13-27
22. Jensen R.T. Natural history of digestive endocrine tumors. In: Mignon M., and Colombel J.F. (Eds). Recent advances in the pathology and management of inflammatory bowel disease and digestive endocrine tumors (1999), John Libbey Eurotext, Paris 192-219
23. Yu F., Venzon D.J., Serrano J., Goebel S.U., Doppman J.L., Gibril F., et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 17 (1999) 615-630
24. Hochwald S.N., Zee S., Conlon K.C., Colleoni R., Louie O., Brennan M.F., et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (2002) 2633-2642
25. Lepage C., Rachet B., and Coleman M.P. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 132 (2007) 899-904
26. Dousset B., Saint-Marc O., Pitre J., Soubrane O., Houssin D., and Chapuis Y. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 20 (1996) 908-914
27. Chung J.C., Choi D.W., Jo S.H., Heo J.S., Choi S.H., and Kim Y.I. Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment. World J Surg 31 (2007) 579-585
28. Musunuru S., Chen H., Rajpal S., Stephani N., McDermott J.C., Holen K., et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 141 (2006) 1000-1005
29. Chen H., Hardacre J.M., Uzar A., Cameron J.L., and Choti M.A. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg 187 (1998) 88-93
30. Chamberlain R.S., Canes D., Brown K.T., Saltz L., Jarnagin W., Fong Y., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 (2000) 432-445
31. Chu Q.D., Hill H.C., Douglass H.O., Driscoll D., Smith J.L., Nava H.R., et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 9 (2002) 855-862
32. Sargent D.J., Wieand H.S., Haller D.G., Gray R., Benedetti J.K., Buyse M., et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23 (2005) 8664-8670
33. Moreno A., Akcakanat A., Munsell M.F., Soni A., Yao J.C., and Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15 (2008) 257-266
34. Kwekkeboom D.J., de Herder W.W., Kam B.L., van Eijck C.H., van Essen M., Kooij P.P., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (2008) 2124-2130